Open AccessDenosumab For The Treatment Of Bisphosphonate-Refractory Hypercalcemia Of Malignancy - A Case Report
Author(s) -
Vishal V Ramteke,
Sudhir Ranjan Dash,
Shubhadeep Bose,
Ritu Jain
Publication year - 2015
Publication title -
journal of medical sciences/journal of medical sciences (srinagar. online)
Language(s) - English
Resource type - Journals
eISSN - 2582-063X
pISSN - 0972-110X
DOI - 10.33883/jms.v18i2.266
Subject(s) - medicine , denosumab , bisphosphonate , malignancy , refractory (planetary science) , bone density conservation agents , osteoclast , bone resorption , rankl , osteoporosis , oncology , surgery , bone density , receptor , physics , activator (genetics) , astrobiology
Hypercalcemia of malignancy caused primarily by tumor-induced bone resorption may lead to renal failure, coma, and death. Patients treated with routine intravenous bisphosphonates may not respond or may relapse on therapy. Denosumab, a monoclonal human antibody which binds to RANKL, inhibits the osteoclast mediated bone resorption and hypercalcemia. We report a case of hypercalcemia in patient with metastatic carcinoma breast refractory to bisphosphonate therapy responding to denosumab and to the best of our knowledge is the first reported case in Indian literature. JMS 2015; 8(2):153-155